Skip to main
ENGN
ENGN logo

ENGN Stock Forecast & Price Target

ENGN Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 13%
Buy 75%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

enGene Holdings Inc. demonstrates strong potential for growth due to its innovative DDX gene delivery platform, which allows for localized delivery of gene therapies to mucosal tissues and other organs. The company has received RMAT designation for detalimogene, positioning it to capture substantial market share, especially in community practice settings, enhanced by promising clinical results and a competitive efficacy profile compared to best-in-class assets. Additionally, the increase in research and development expenses reflects a commitment to advancing its pivotal LEGEND study, further substantiating a positive outlook for future performance and valuation metrics.

Bears say

enGene Holdings Inc faces significant challenges that negatively impact its outlook. The ongoing LEGEND trial has shown disappointing results for Detalimogene, with emerging safety concerns and changing regulatory requirements that may hinder approval timelines. Additionally, the company is at risk of increased capital requirements leading to equity dilution, compounded by heightened competitive pressures in the biotechnology space where larger, more established firms dominate.

ENGN has been analyzed by 8 analysts, with a consensus rating of Buy. 13% of analysts recommend a Strong Buy, 75% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Engene Holdings Inc (ENGN) Forecast

Analysts have given ENGN a Buy based on their latest research and market trends.

According to 8 analysts, ENGN has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Engene Holdings Inc (ENGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.